Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Pharm ; 16(5): 1839-1850, 2019 05 06.
Article in English | MEDLINE | ID: mdl-30974944

ABSTRACT

Protein tyrosine phosphatase 1B (PTP1B) is a widely confirmed target of the type 2 diabetes mellitus (T2DM) treatment. Herein, we reported a highly specific PTP1B inhibitor 2,2',3,3'-tetrabromo-4,4',5,5'-tetrahydroxydiphenylmethane (compound 1), which showed promising hypoglycemic activity in diabetic BKS db mice. With the IC50 value of 2.4 µM, compound 1 could directly bind to the catalytic pocket of PTP1B through a series of hydrogen bonds. Surface plasmon resonance analysis revealed that the target affinity [KD (equilibrium dissociation constant) value] of compound 1 binding to PTP1B was 2.90 µM. Moreover, compound 1 could activate the insulin signaling pathway in C2C12 skeletal muscle cells. We further evaluated the long-term effects of compound 1 in diabetic BKS db mice. Notably, oral administration of compound 1 significantly reduced the blood glucose levels of diabetic mice with increasing insulin sensitivity. In addition, the dyslipidemia of diabetic mice was also significantly improved by compound 1 gavage. The histological experiments showed that compound 1 treatment significantly ameliorated the disordered hepatic and pancreatic architecture and increased the glycogen content in the liver tissues as well as improved the insulin secretion function of pancreas. Taken together, our results manifested that the natural product compound 1 was a highly specific PTP1B inhibitor, which could activate insulin signaling pathway and ameliorate hyperglycemia and dyslipidemia in diabetic BKS db mice.


Subject(s)
Benzhydryl Compounds , Diabetes Mellitus, Type 2 , Hypoglycemic Agents , Plant Extracts , Protein Tyrosine Phosphatase, Non-Receptor Type 1 , Animals , Male , Mice , Administration, Oral , Benzhydryl Compounds/administration & dosage , Benzhydryl Compounds/chemistry , Benzhydryl Compounds/pharmacology , Benzhydryl Compounds/therapeutic use , Catalytic Domain , Cell Line , Diabetes Mellitus, Type 2/drug therapy , Glycogen/metabolism , Hydrogen Bonding , Hypoglycemic Agents/administration & dosage , Hypoglycemic Agents/chemistry , Hypoglycemic Agents/pharmacology , Hypoglycemic Agents/therapeutic use , Inhibitory Concentration 50 , Insulin/metabolism , Insulin Resistance , Liver/drug effects , Liver/metabolism , Mice, Inbred C57BL , Mice, Inbred NOD , Molecular Docking Simulation , Myoblasts/drug effects , Myoblasts/metabolism , Plant Extracts/administration & dosage , Plant Extracts/chemistry , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , Protein Tyrosine Phosphatase, Non-Receptor Type 1/antagonists & inhibitors , Protein Tyrosine Phosphatase, Non-Receptor Type 1/chemistry , Protein Tyrosine Phosphatase, Non-Receptor Type 1/isolation & purification , Rhodophyta/chemistry , Signal Transduction/drug effects
2.
Biochem Mol Biol Educ ; 45(5): 403-410, 2017 Sep.
Article in English | MEDLINE | ID: mdl-28294503

ABSTRACT

Here, we present a 10-week project-oriented laboratory module designed to provide a course-based undergraduate research experience in biochemistry that emphasizes the importance of biomolecular structure and dynamics in enzyme function. This module explores the impact of mutagenesis on an important active site loop for a biomedically-relevant human enzyme, protein tyrosine phosphatase 1B (PTP1B). Over the course of the semester students guide their own mutant of PTP1B from conception to characterization in a cost-effective manner and gain exposure to fundamental techniques in biochemistry, including site-directed DNA mutagenesis, bacterial recombinant protein expression, affinity column purification, protein quantitation, SDS-PAGE, and enzyme kinetics. This project-based approach allows an instructor to simulate a research setting and prepare students for productive research beyond the classroom. Potential modifications to expand or contract this module are also provided. © 2017 by The International Union of Biochemistry and Molecular Biology, 45(5):403-410, 2017.


Subject(s)
Biochemistry/education , Laboratories , Protein Tyrosine Phosphatase, Non-Receptor Type 1/chemistry , Protein Tyrosine Phosphatase, Non-Receptor Type 1/metabolism , Research/education , Humans , Protein Conformation , Protein Tyrosine Phosphatase, Non-Receptor Type 1/isolation & purification , Students
3.
J Microbiol Biotechnol ; 24(2): 152-9, 2014 Feb 28.
Article in English | MEDLINE | ID: mdl-24248091

ABSTRACT

The regulation of protein tyrosine phosphorylation is mediated by protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs) and is essential for cellular homeostasis. Coexpression of PTKs with PTPs in Pichia pastoris was used to facilitate the expression of active PTKs by neutralizing their apparent toxicity to cells. In this study, the gene encoding phosphatase PTP1B with or without a blue fluorescent protein or peroxisomal targeting signal 1 was cloned into the expression vector pAG32 to produce four vectors. These vectors were subsequently transformed into P. pastoris GS115. The tyrosine kinases EGFR-2 and PDGFRß were expressed from vector pPIC3.5K and were fused with a His-tag and green fluorescent protein at the N-terminus. The two plasmids were transformed into P. pastoris with or without PTP1B, resulting in 10 strains. The EGFR-2 and PDGFRß fusion proteins were purified by Ni(2+) affinity chromatography. In the recombinant P. pastoris, the PTKs co-expressed with PTP1B exhibited higher kinase catalytic activity than did those expressing the PTKs alone. The highest activities were achieved by targeting the PTKs and PTP1B into peroxisomes. Therefore, the EGFR-2 and PDGFRß fusion proteins expressed in P. pastoris may be attractive drug screening targets for anticancer therapeutics.


Subject(s)
Gene Expression , Pichia/genetics , Pichia/metabolism , Protein Tyrosine Phosphatase, Non-Receptor Type 1/analysis , Protein-Tyrosine Kinases/analysis , Receptor, Platelet-Derived Growth Factor beta/analysis , Cloning, Molecular , Metabolic Engineering/methods , Protein Tyrosine Phosphatase, Non-Receptor Type 1/genetics , Protein Tyrosine Phosphatase, Non-Receptor Type 1/isolation & purification , Protein-Tyrosine Kinases/genetics , Protein-Tyrosine Kinases/isolation & purification , Receptor, Platelet-Derived Growth Factor beta/genetics , Receptor, Platelet-Derived Growth Factor beta/isolation & purification , Recombinant Proteins/analysis , Recombinant Proteins/genetics , Recombinant Proteins/isolation & purification , Transformation, Genetic
4.
Hybridoma (Larchmt) ; 31(3): 209-13, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22741586

ABSTRACT

Protein tyrosine phosphatase 1B (PTP1B), a member of the protein tyrosine phosphatase (PTP) family, plays a crucial role in metabolic signaling, with insulin and leptin signaling being well studied. New evidence indicates that PTP1B is also involved in cancer. In the present study, we report on the establishment of a monoclonal antibody specific for catalytic domain of PTP1B (PTP1Bc) generated through the hybridoma method. The monoclonal antibody is measured to have a titer of 4.1×10(6) against PTP1Bc in indirect ELISA. Western blot and immunofluorescent analyses indicated that this antibody can specifically combine native PTP1B in MDA-MB-231 and MDA-MB-453 cells. This monoclonal antibody against PTP1Bc can help enhance the understanding of PTP1B-related physiological and pathological mechanisms and may act as a therapeutic agent for diabetes, obesity, and cancer in the future.


Subject(s)
Antibodies, Monoclonal, Murine-Derived/immunology , Immunoglobulin G/immunology , Protein Tyrosine Phosphatase, Non-Receptor Type 1/immunology , Recombinant Fusion Proteins/immunology , Animals , Antibodies, Monoclonal, Murine-Derived/biosynthesis , Antibody Specificity , Blotting, Western , Catalytic Domain/immunology , Cell Line, Tumor , Female , Fluorescent Antibody Technique, Indirect , Humans , Hybridomas , Immunoglobulin G/biosynthesis , Mice , Mice, Inbred BALB C , Protein Tyrosine Phosphatase, Non-Receptor Type 1/isolation & purification , Protein Tyrosine Phosphatase, Non-Receptor Type 1/metabolism , Recombinant Fusion Proteins/isolation & purification , Recombinant Fusion Proteins/metabolism , Titrimetry
5.
Eur J Med Chem ; 46(6): 2243-51, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21453996

ABSTRACT

The aim of the current study was to investigate the oral antidiabetic activity of four structurally-related triterpenic acids: ursolic (RE-01), oleanolic (RE-02), moronic (RE-03) and morolic (RE-04) acids. STZ-nicotinamide diabetic rats were treated with these triterpenes (50 mg/kg) and the antidiabetic effects in acute experiment were determined. All compounds showed significant antidiabetic activity in comparison with control group (p<0.05). The in vitro inhibitory activity of compounds against protein tyrosine phosphatase 1B (PTP-1B) was also evaluated. At 50 µM, the enzymatic activity was almost completely inhibited. All compounds were docked with a crystal structure of PTP-1B. Docking results suggested the potential binding of the triterpenic acids in a binding pocket next to the catalytic site. An extensive hydrogen bond network with the carboxyl group and Van der Waals interactions stabilize the protein-ligand complexes.


Subject(s)
Diabetes Mellitus, Experimental/drug therapy , Enzyme Inhibitors/pharmacology , Hypoglycemic Agents/pharmacology , Protein Tyrosine Phosphatase, Non-Receptor Type 1/antagonists & inhibitors , Triterpenes/pharmacology , Animals , Diabetes Mellitus, Experimental/enzymology , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Enzyme Activation/drug effects , Enzyme Inhibitors/chemistry , Humans , Hypoglycemic Agents/chemistry , Male , Models, Molecular , Molecular Conformation , Protein Tyrosine Phosphatase, Non-Receptor Type 1/isolation & purification , Protein Tyrosine Phosphatase, Non-Receptor Type 1/metabolism , Rats , Rats, Wistar , Recombinant Proteins/antagonists & inhibitors , Recombinant Proteins/isolation & purification , Recombinant Proteins/metabolism , Stereoisomerism , Structure-Activity Relationship , Triterpenes/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...